Positioning of proteasome inhibitors in therapy of solid malignancies

Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received con...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology Jg. 81; H. 2; S. 227 - 243
Hauptverfasser:	Roeten, Margot S. F., Cloos, Jacqueline, Jansen, Gerrit
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2018 Springer Nature B.V
Schlagworte:	Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cancer Cancer Research Colon Cytotoxic Reviews Drug Resistance, Neoplasm Head & neck cancer Humans Medicine Medicine & Public Health Molecular modelling Neoplasms - drug therapy Oncology Pancreas Pharmacology/Toxicology Protease inhibitors Proteasome Endopeptidase Complex - chemistry Proteasome Endopeptidase Complex - drug effects Proteasome inhibitors Proteasome Inhibitors - pharmacology Proteasome Inhibitors - therapeutic use Proteasomes Review Review Article Solid tumors Targeted cancer therapy Ubiquitin Carfilzomib Bortezomib Solid tumors Drug resistance Proteasome inhibitors
ISSN:	0344-5704, 1432-0843, 1432-0843
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received continuing interest for the treatment of solid tumors. In this review, we summarize the current positioning of proteasome inhibitors in the treatment of common solid malignancies (e.g., lung, colon, pancreas, breast, and head and neck cancer), addressing topics of their mechanism(s) of action, predictive factors and molecular mechanisms of resistance.
Bibliographie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Literature Review-3 ObjectType-Review-3 content type line 23
ISSN:	0344-5704 1432-0843 1432-0843
DOI:	10.1007/s00280-017-3489-0